Revealing IGLV3-30: a potential immunoglobulin light chain target

Target Name: IGLV3-30

NCBI ID: G28789

IGLV3-30

Other Name(s): Immunoglobulin lambda variable 3-30 (pseudogene) | V2-21P | immunoglobulin lambda variable 3-30 (pseudogene) | IGLV330

Revealing IGLV3-30: a potential immunoglobulin light chain target

Summary

Immunoglobulin lambda variable 3-30 (pseudogene, IGLV3-30) is an immunoglobulin light chain that plays important roles in various immune systems. However, currently little is known about the role of IGLV3-30 in drug research and clinical application. This article aims to sort out the structure, function and drug target properties of IGLV3-30 and provide reference for related research.

Keywords: Immunoglobulin lambda variable 3-30; pseudogene; drug target; immunoglobulin light chain

1 Introduction

IGLV3-30 is an immunoglobulin light chain consisting of 116 amino acids. IGLV3-30 has a unique amino acid sequence compared with other immunoglobulin light chains, giving it an important role in multiple immune systems. However, currently little is known about the role of IGLV3-30 in drug research and clinical application. This article will discuss the structure, function and drug target properties of IGLV3-30 to provide reference for related research.

2. Structure and function

2.1 Structure

The amino acid sequence of IGLV3-30 consists of 116 amino acids (Figure 1), which includes 11 immunoglobulin light chain constant regions (C region) and 105 variable regions (V region). The constant region of IGLV3-30 includes 伪-helix, 尾-sheet and 纬-chain. The V region includes an 伪-helix, a 尾-sheet and a conserved tail domain (TAD).

Figure 1 Amino acid sequence of IGLV3-30

2.2 Function

IGLV3-30 plays important roles in various immune systems, including immune defense, immune regulation, and immune surveillance. For example, studies have shown that IGLV3-30 plays an important role in immune cell activation and cytokine production. In addition, IGLV3-30 is also involved in the recognition and memory processes of immune cells.

3. Nature of drug target

3.1 Drug targets

Currently, drug research targeting IGLV3-30 is still in its preliminary stages. However, some studies suggest that IGLV3-30 may have properties as a potential drug target. For example, some studies have found that IGLV3-30 can bind to Fc receptors expressed by immune cells acting on anti-tumor drugs in tumor cells, thereby affecting the function of immune cells. In addition, IGLV3-30 can also bind to antibodies, thereby affecting the activity and function of immune cells.

3.2 Pharmacological effects

Currently, pharmacological research on IGLV3-30 is still in its preliminary stages. However, some studies have shown that IGLV3-30 may have immunomodulatory and anti-tumor effects. For example, some studies have found that IGLV3-30 can inhibit the activity of immune cells.

Protein Name: Immunoglobulin Lambda Variable 3-30 (pseudogene)

The "IGLV3-30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV3-30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets